GENMAB'S R&D TO COMMERCIALISATION JOURNEY (REDUCE; -10% DOWNSIDE)
03/09/21 -" Soon after our last teaser (GENMAB’S LIFE BEYOND DARZALEX) in May 2020, Genmab (Reduce, Denmark) announced a big oncology pact with AbbVie (US pharma heavyweight). Importantly, the Danish biotech – ..."
Pages
47
Language
English
Published on
03/09/21
You may also be interested by these reports :
03/02/26
Roche’s shares have recovered c.34% in the last three months and are now close to the highs witnessed in April 2022, as investors eventually recover ...
29/01/26
The 2025 performance delivered on the management’s guidance, backed by a strong showing from the cornerstone immunology medicine Dupixent, newly ...
29/01/26
Roche finished the year on a strong note, backed by healthy performances across key focus areas. Even the 2026 guidance was encouraging. The ...
28/01/26
Lonza’s full-year 2025 CDMO performance surpassed management’s guidance. Top-line growth was driven by strong double-digit increases in Integrated ...